Peptide Enforcement Tracker: FDA Warning Letters on Peptides, DOJ Cases and Lawsuits, 2025 to 2026
This page is a running, dated record of enforcement and regulatory actions against companies that sell research peptides and GLP-1 drugs in the United States: FDA warning letters, Department of Justice cases, lawsuits brought by drug manufacturers, state attorney general actions, and FDA proposals or advisory votes that change what can be sold or compounded. It covers April 2025 to 3 November 2026 and currently lists 33 entries, newest first. Each row links to the document it rests on.
If you are researching a compound rather than a company, the stack builder narrows the options to your goal in 60 seconds, and Peptulator does the syringe unit maths for any vial.
How entries are sourced. An action is listed only if the Bureau could open a primary source for it: the FDA's warning-letter database or press pages at fda.gov, a justice.gov press release, a state attorney general's release, or the company's own investor release. Where no primary page exists or it does not carry the fact in question (for example, advisory committee tallies), a named major outlet is cited instead. Every source link was fetched live on 25 September 2026, the three entries added on 14 October 2026 were fetched that day, and the 20 October entry that day (its status rechecked on 23 October). Anything the Bureau could not verify against a source with a date on it is left out, and the omissions are listed at the end of the page. The date in the first column is the date on the document; where the FDA published a letter later, the posting date is given in the row.
Disclosure. Peptide Bureau earns affiliate commission from some research-peptide vendors; the terms are on the disclosures page. Vendors appear in this tracker on the strength of the public record alone, whether or not the Bureau has any relationship with them. As of this update, none of the vendors the Bureau scores appears in the table.
Latest from the news desk
FDA warns RonanRx over "American made" compounded GLP-1s (8 November). HHS published its peptide compounding policy: six peptides, ten conditions (31 October). A drug-safety group asked the FDA to block compounding of seven peptides (27 October, updated 31 October). Peptide recalls in the FDA's October enforcement reports (27 October). RFK Jr. wants a regulated peptide marketplace: what the record shows (23 October, updated 31 October). The FDA's peptide interim access policy is at the White House (20 October, updated 31 October with the published text). Are peptides legal now? The temporary sale plan, checked (14 October, updated 31 October). Black-market retatrutide (14 October). All pieces: Peptide News.
Vendor Watch · free
Know before you order: an email when a vendor we cover is shut down, seized, fails a lab test or changes its code.
Plus, every Friday, the week's lowest price per mg for each compound at the vendors we score, all of which publish batch COAs. Your 5-minute vendor check sheet opens as soon as you confirm.
Every alert is checked by a person and cites its source before it is sent. One-click unsubscribe. Research use only.
Buying research peptides? Our top-scored source right now: Amino Club
The vendor Bureau readers order from most this year, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only. Affiliate link: we earn a commission if you order.
Visit Amino Club Compare all vendorsThe tracker: 33 actions, newest first
| Date | Who | Action type | What it says | Source |
|---|---|---|---|---|
| 2026-10-30 | RonanRx, Inc. dba RonanRx (Elgin, Texas) | FDA warning letter | The FDA says the online seller's claims for compounded semaglutide and tirzepatide are false or misleading: labels naming RonanRx when it is not the compounder, claims that read as FDA approval, and "American made" and "farm-to-table drugs". The letter says FDA records list no U.S. establishment registered with the FDA as the maker of semaglutide or tirzepatide active ingredient intended for compounding. Posted 3 November. Our story. | FDA letter 737905 |
| 2026-10-30 | HHS (Office of the Secretary) | HHS enforcement discretion policy (published) | HHS filed a notice on 28 October and the Federal Register published it on 30 October (91 FR 68526, Docket HHS-OASH-2026-0496, RIN 0910-ZD94): "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances". HHS says it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding with BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 when ten conditions are met, including a patient-specific prescription, an FDA-registered source with a certificate of analysis, a single active ingredient and adverse event reporting. The policy calls itself interim, is not an FDA approval, and the notice says it is not binding on HHS or the public. Written comments closed on regulations.gov on 13 November 2026 (115 posted); as of 14 November HHS had published no final version. | Federal Register notice; HHS policy (PDF); Bureau news piece |
| 2026-10-14 | FDA (submitted to the White House Office of Information and Regulatory Affairs) | FDA proposal (under review) | The FDA sent an action titled "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94, stage: notice, no legal deadline) for White House review. Its text and the peptides it covers had not been published as of 23 October, when it was still pending review with six outside meetings logged; the AP, citing two unnamed people, reported it would let pharmacies temporarily compound popular peptides including BPC-157. Update 28 October: the review concluded on 27 October as "Consistent with Change"; the text was still unpublished on 28 October. Update 31 October: HHS published its enforcement discretion policy on 30 October under the same RIN (see the 30 October row above). | reginfo.gov listing; Bureau news piece |
| 2026-10-14 | Apothecary Pharma LLC (Cary, NC), Carolina Infusion, LLC (Ridgeland, SC), Houston Rx LLC (Houston, TX), Centric Compounding LLC (Tomball, TX) | FDA recalls (Enforcement Report) | The FDA's Enforcement Reports of 14 and 21 October list 12 voluntary Class II recalls of tirzepatide, semaglutide and sermorelin from the first three firms, for lack of assurance of sterility or lack of process control, and one glutathione blend from Centric Compounding recalled over out-of-specification bacterial endotoxin results, not yet classified. The records give no illness count. | FDA Enforcement Report data, 14 Oct; Bureau news piece |
| 2026-10-08 | Eli Lilly and Company v. American Peptides LLC, LiveWell Peptides, Cenexa Labs LLC, Medrein Health & Aesthetics, Medshape Weight Loss Clinic LLC | Lawsuit (manufacturer) | Lilly filed five more complaints across several federal courts alleging the businesses unlawfully sell and promote copies of retatrutide, its investigational obesity drug, following the six suits filed in August. The claims are allegations, not findings. | Bloomberg Law, 8 Oct 2026; Bureau news piece |
| 2026-09-29 | Swapnadip Roy and Vicky Ramancha (US Attorney, M.D. Florida; DOJ Criminal Division) | DOJ case (indictment) | A federal grand jury charged two Indian nationals with smuggling conspiracy, smuggling and counterfeit-drug counts over counterfeit Ozempic allegedly obtained in China and sold to US distributors from at least July 2023 to April 2024; Roy was extradited from Italy. An indictment is an allegation, not a finding of guilt. | DOJ press release |
| 2026-09-23 | Online Generic Medicine (onlinegenericmedicine.com) | FDA warning letter | The FDA says the website sold unapproved and misbranded injectable semaglutide, marketed as "Semanat Injection (Semaglutide)", without requiring a prescription. It reviewed the site on 26 August and 2 September and asked for a written response within 15 business days. Posted 6 October. | FDA letter 737806 |
| 2026-09-18 | Ryan Fields, Pinned Aminos (US Attorney, District of Connecticut) | DOJ case (jury verdict) | A New Haven jury convicted the operator of pinnedaminos.com and projectaminos.com of conspiracy to introduce misbranded or unapproved drugs and to smuggle, and of money laundering conspiracy. The DOJ says the site's "intended for laboratory and research use only" disclaimer was false and that the pair gave customers directions on dosage; more than 10,000 parcels, over $1.4 million. Co-defendant Lisa Mahan was sentenced on 13 August 2026 to three years' probation. Announced 21 September. | DOJ press release |
| 2026-09-18 | Empower Clinic Services, LLC dba Empower Pharmacy (Houston, Texas) | FDA warning letter | The FDA says the 503A pharmacy compounded semaglutide and tirzepatide products that were essentially copies of approved drugs in inordinate amounts, called the claimed differences "pretextual" given the volume, and cited insanitary conditions found at a November 2025 inspection. Posted 22 September. | FDA letter 738238; CBS News, 24 Sept 2026 |
| 2026-08-24 | TXP Innovations LLC dba Tex Peptides (Dallas, Texas) | FDA warning letter | Semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin, PT-141 and bacteriostatic water sold as research products are unapproved new drugs, because the website shows they are intended for human use. Posted 1 September. | FDA letter 735067 |
| 2026-08-24 | Royal Peptides LLC | FDA warning letter | Tirzepatide, semaglutide, retatrutide, SS-31, PT-141, tesamorelin and a product listed as "BIMORELIN" are unapproved new drugs; the letter cites bacteriostatic water sold alongside a "peptide guide" and "peptide calculator" as evidence of intended human use. Posted 1 September. | FDA letter 734884 |
| 2026-08-24 | Peptide Partners LLC (Sarasota, Florida) | FDA warning letter | Coded GLP-1 S, GLP-2 T and GLP-3 Reta (semaglutide, tirzepatide, retatrutide), SS-31, tesamorelin, PT-141 and a reconstitution solution are unapproved new drugs despite research-use-only labels. Posted 1 September. | FDA letter 735063 |
| 2026-08-24 | Peak Performance Peptides | FDA warning letter | Bac water, GLP-3R (retatrutide), semaglutide, SS-31, PT-141 and tesamorelin are unapproved new drugs; selling bacteriostatic water as a solvent is cited as providing the means to prepare an injectable drug. Posted 1 September. | FDA letter 735127 |
| 2026-08-24 | NuScience Peptides LLC | FDA warning letter | Tirzepatide, semaglutide, retatrutide, survodutide, mazdutide, PT-141, tesamorelin, a tesamorelin and ipamorelin blend and BAC water are unapproved new drugs; the letter cites bacteriostatic water sold alongside a "peptide calculator". Posted 1 September. | FDA letter 733652 |
| 2026-08-12 | Eli Lilly and Company v. Aesthetic Envy, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides, Lone Star Peptide | Lawsuit (manufacturer) | Lilly filed six federal lawsuits in California and Texas against sellers of retatrutide, an investigational drug not approved anywhere, and said it has referred more than 200 individuals and entities to the FDA, DOJ, state attorneys general and licensing boards. | Lilly news release; CBS News, 12 Aug 2026 |
| 2026-07-30 | Paradigm Peptides: Matthew J. Kawa and Jennifer L. Stechkober (US Attorney, N.D. Indiana) | DOJ case (sentencing) | The owner was sentenced to 70 months and his sister to 16 months after pleading guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead, with a $5 million money judgment against Kawa; CBS reported he admitted forging laboratory certificates. | DOJ press release; CBS News, 30 July 2026 |
| 2026-07-23 to 24 | FDA Pharmacy Compounding Advisory Committee | FDA advisory vote | The committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A bulks list while emideltide (DSIP) failed 6 to 7; FDA staff had recommended against each one, and the votes are not binding. | FDA meeting page; STAT, 24 July 2026; Bureau analysis |
| 2026-06-17 | Wholesale Peptide (Brooksville, Florida) | FDA warning letter | Prostamax and gonadorelin sold as "research use only" are unapproved new drugs because the product labeling and website show they are intended for human use. Posted 23 June. | FDA letter 729447 |
| 2026-06-16 | 25 telehealth companies | FDA warning letters (batch) | The FDA posted warning letters to 25 telehealth companies over their marketing of compounded GLP-1 drugs, including semaglutide and tirzepatide products. | RAPS Regulatory Focus, 16 June 2026 |
| 2026-04-30 | FDA | FDA proposal | The FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substances, with comments due 29 June 2026. | FDA press announcement |
| 2026-04-01 | Justin Bradley Watkins, osteopathic physician (US Attorney, District of Utah) | DOJ case (indictment) | A federal grand jury indicted a Utah physician accused of buying unapproved peptides from China, including tirzepatide, semaglutide, retatrutide and BPC-157, and selling them to more than 200 patients; an indictment is an allegation, not a finding of guilt. | DOJ press release |
| 2026-03-31 | Gram Peptides (Rancho Santa Fe, California) | FDA warning letter | Retatrutide (sold as "GLP-1-R peptide"), tirzepatide and bacteriostatic water for injection are unapproved new drugs despite "Research Use Only" labels. Posted 7 April. | FDA letter 721806 |
| 2026-03-31 | Lovega LLC dba Pink Pony Peptides (Wellington, Florida) | FDA warning letter | "GLP-2 TZ," "GLP-3 RT" and bacteriostatic water are unapproved new drugs intended for human use. Posted 7 April. | FDA letter 721088 |
| 2026-03-31 | PekCura Labs (Pensacola, Florida) | FDA warning letter | "GLP-1-S," "GLP-2-T," "GLP-3-R" and bacteriostatic water are unapproved new drugs intended for human use. Posted 7 April. | FDA letter 721709 |
| 2026-03-31 | Prime Sciences (Scottsdale, Arizona) | FDA warning letter | Cagrilintide, "GLP1-R," "GLP1-S," "GLP1-T," mazdutide and BAC water sold in a reconstitution kit are unapproved new drugs intended for human use. Posted 7 April. | FDA letter 721805 |
| 2026-03-31 | Mile High Compounds LLC (Clifton, Colorado) | FDA warning letter | "GLP-1 SM," "GLP-2 TRZ," "GLP-3 RT" and BAC water are unapproved new drugs; the FDA reviewed both the website and the company's linked community forum. Posted 7 April. | FDA letter 721600 |
| 2026-03-03 | 30 telehealth companies | FDA warning letters (batch) | The FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products on their websites. | FDA press announcement |
| 2026-02-06 | FDA and HHS; Hims & Hers | FDA statement and DOJ referral | The FDA said it would restrict GLP-1 active ingredients used in mass-marketed, non-approved compounded drugs, and the HHS general counsel said he had referred Hims & Hers to the Justice Department over its plan to offer a compounded version of a weight-loss pill. | STAT, 6 Feb 2026 |
| 2025-09-09 | Hims & Hers Health, Inc. dba Hims | FDA warning letter | Website claims such as "Same active ingredient as Ozempic and Wegovy" for compounded semaglutide are false or misleading and make the products misbranded. Posted 16 September 2025. | FDA letter 716567 |
| 2025-09-09 | GLP-1 Solution (online seller, Berlin address) | FDA warning letter | Retatrutide sold to US consumers online is an unapproved new drug and misbranded; the site also offered compounded semaglutide and tirzepatide. Posted 16 September 2025. | FDA letter 715883 |
| 2025-08-05 | Connecticut Attorney General; Triggered Brand | State AG settlement | Triggered Brand agreed to stop selling "research grade" GLP-1 drugs, resolving the state's May lawsuit, with a $300,000 judgment suspended after $18,500. | Connecticut AG release |
| 2025-05-21 | Connecticut Attorney General; Triggered Brand; Made In China | State AG lawsuit | The attorney general sued Florida-based Triggered Brand under the Connecticut Unfair Trade Practices Act for selling "research grade" GLP-1 peptides to consumers without prescriptions, and issued a civil investigative demand to the Made In China marketplace. | Connecticut AG release |
| 2025-04-23 | Eli Lilly and Company v. Mochi Health, Willow Health, Fella Health and Delilah, Henry Meds | Lawsuit (manufacturer) | Lilly sued telehealth companies selling compounded tirzepatide, alleging, in Mochi Health's case, that patients were switched to versions with additives such as niacinamide. | NPR, 23 Apr 2025 |
By type: 16 individual FDA warning letters, 2 FDA batches covering 55 further letters to telehealth companies, 2 FDA proposals, 1 HHS enforcement discretion policy, 1 set of FDA recalls, 1 FDA advisory vote, 1 FDA statement with an HHS referral to the DOJ, 4 DOJ criminal cases, 3 rounds of manufacturer lawsuits against 15 defendants, and 2 state attorney general actions.
What the pattern shows
Research-use-only labels have not worked as a defence. All eleven 2026 letters to research-peptide sellers in the table (the five in March, Wholesale Peptide in June and the five in August) use the same construction: despite labels such as "for research use only" or "not for human consumption," the FDA says evidence on the website shows the products are intended to be drugs for human use. Ten of the eleven name bacteriostatic water, either as a product in its own right or as evidence that the seller was supplying the means to prepare an injection. The August letters to Royal Peptides and NuScience go a step further and cite a "peptide calculator" on the seller's site.
The product list widened. The March letters dealt almost entirely with GLP-class compounds sold under coded names (GLP-1 S, GLP-2 T, GLP-3 R). The June letter applied the same template to gonadorelin and Prostamax, and by August the letters also covered SS-31, PT-141, tesamorelin and a tesamorelin and ipamorelin blend.
Letters now arrive every few months. In 2026 the FDA dated letters to peptide or GLP-1 sellers on 31 March, 17 June, 24 August, 18 September, 23 September and 30 October, and sent telehealth batches announced on 3 March and reported on 16 June. Each letter to a named seller carries an FDA posting date four to thirteen days after the date on the letter.
Enforcement is no longer only letters. 2026 added a criminal sentence of 70 months for a research-peptide vendor, a September jury verdict against the Pinned Aminos operator in which the DOJ called the research-use disclaimer false, a federal indictment of a physician for selling imported peptides to patients, eleven lawsuits by Lilly over retatrutide (six in August, five in October), and an HHS referral of a listed telehealth company to the DOJ. The 2025 Connecticut case shows state attorneys general using consumer-protection law against "research grade" GLP-1 sellers.
Compounding is moving in two directions. For GLP-1 drugs the FDA is closing doors: the April 2026 proposal would keep semaglutide, tirzepatide and liraglutide off the 503B bulks list, and the Empower letter, which CBS News described as the first time the FDA has waded into when customising a medication becomes mass-copying, targets a 503A pharmacy. For a group of older research peptides the advisory committee voted the other way in July, though no rule has followed and FDA staff opposed every one. The Bureau's PCAC vote analysis sets out what that vote does and does not change, and the legal status guide explains the underlying law.
What is not in the table, and why
Peptide Sciences, one of the best-known research-peptide storefronts, posted a notice saying it had voluntarily shut down operations. It is omitted because the Bureau found no primary document or major-outlet report that fixes the date; the notice itself is undated and the widely repeated 6 March 2026 date comes from trade blogs and law-firm posts. Other vendor closures in the same period (Science.bio, Strate Labs, Amino Asylum) are left out because their only sources are the vendors' own notices or trade sites, which fall outside the sourcing rule above. The Bureau's vendor shutdowns page records what those notices say. The tracker also does not list letters the FDA has not posted, private civil suits between competitors, or the 2025 telehealth letter wave beyond the two September 2025 letters whose pages the Bureau opened.
See also: survodutide legal status and trial data.
Frequently Asked Questions
What are the latest FDA warning letters on peptides?
The most recent letters to research-peptide sellers are the five dated 24 August 2026 and posted on 1 September: Peptide Partners, Peak Performance Peptides, NuScience Peptides, TXP Innovations dba Tex Peptides and Royal Peptides. They cover semaglutide, tirzepatide, retatrutide, SS-31, PT-141 and tesamorelin, and NuScience's letter also names mazdutide and survodutide. Later FDA letters in the table went to Empower Pharmacy on 18 September 2026, to an online semaglutide seller, Online Generic Medicine, on 23 September, and to RonanRx, an online seller of compounded semaglutide and tirzepatide, on 30 October (posted 3 November).
Do research use only labels protect peptide sellers from the FDA?
No. All eleven 2026 letters to research-peptide sellers in the table use the same construction: despite labels such as research use only or not for human consumption, the FDA says evidence on the website shows the products are intended to be drugs for human use. Ten of the eleven name bacteriostatic water, and the August letters to Royal Peptides and NuScience also cite a peptide calculator on the seller's site. In the Pinned Aminos case, the Department of Justice said the site's laboratory and research use only disclaimer was false.
How many FDA warning letters did peptide sellers get in 2026?
The table lists eleven letters to research-peptide sellers in 2026: five on 31 March (Gram Peptides, Pink Pony Peptides, PekCura Labs, Prime Sciences and Mile High Compounds), one on 17 June (Wholesale Peptide) and five on 24 August. Separately, the FDA announced warning letters to 30 telehealth companies on 3 March and sent 25 more, reported on 16 June, over compounded GLP-1 marketing, and wrote to Empower Pharmacy on 18 September, Online Generic Medicine on 23 September and RonanRx on 30 October.
Which peptide sellers have faced criminal or civil cases?
Paradigm Peptides' owner was sentenced to 70 months and a co-defendant to 16 months on 30 July 2026, with a 5 million dollar money judgment against the owner. A jury convicted the Pinned Aminos operator on 18 September 2026. A Utah physician was indicted on 1 April 2026 over imported peptides, which is an allegation, not a finding. Eli Lilly filed six retatrutide lawsuits on 12 August and five more on 8 October 2026, and Connecticut's attorney general sued Triggered Brand in May 2025 and settled in August 2025.
Will the FDA allow compounding of peptides like BPC-157?
Through enforcement discretion for now, not through approval. The FDA's Pharmacy Compounding Advisory Committee voted on 23 and 24 July 2026 to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A bulks list, although FDA staff had recommended against each one and the votes are not binding. On 30 October 2026 HHS published an interim policy saying it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician that compounds a single-ingredient product from BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 when ten conditions are met. It applies until each substance is addressed in a final rule on the 503A bulks list, and it is not an FDA approval.
How to cite this page
The table is published under a Creative Commons Attribution 4.0 licence: you may reproduce, chart or adapt it, including commercially, with credit to Peptide Bureau and a link to this page. Suggested citation:
Peptide Bureau, "Peptide and GLP-1 Enforcement Tracker," updated 20 October 2026, https://peptidebureau.com/peptide-enforcement-tracker.html
The permalink above will not change when entries are added. Each row also has its own anchor, formed from its date and name, for example https://peptidebureau.com/peptide-enforcement-tracker.html#2026-09-18-empower-pharmacy. For the underlying facts, cite the primary source linked in each row as well.
Corrections
If a date, name or summary here is wrong, or you know of a verifiable action that is missing, email [email protected] with a link to the source. Corrections are dated on this page.
This page reports public enforcement records. It is not legal or medical advice, and a warning letter or lawsuit is an allegation by the agency or company that issued it, not a court finding, unless the row says otherwise.